

Protect Our Care: Johnson & Johnson is cashing in while leaving seniors behind

Posted on Friday, Aug 25, 2023

>> **WisPolitics is now on the State Affairs network. Get custom keyword notifications, bill tracking and all WisPolitics content. [Get the app or access via desktop.](#)**

WISCONSIN - In the coming days, the Biden administration is set to announce the first round of drugs eligible for lower prices under the Medicare Drug Negotiation Program created by the Inflation Reduction Act. Ahead of the drug announcement, Protect Our Care is highlighting drugs that will likely be eligible for negotiation.

Today's focus is Johnson & Johnson's Xarelto, which is a blood thinner that could qualify for negotiation. Xarelto costs patients an average of \$6,240 annually, an unthinkable sum for seniors with limited means or on fixed incomes. Meanwhile, Johnson & Johnson has been raking in billions of dollars on the sale of this drug alone, increasing its price by 126 percent since 2012. Read more about Xarelto and other drugs that could qualify for lower prices under the Inflation Reduction Act [here](#).

Xarelto (Johnson & Johnson*)

Blood thinner drug marketed
 without competition for 12 years

IMPACT ON MEDICARE PATIENTS



Used by **1,258,010**
 Medicare beneficiaries
 in 2021



\$1,340 average
 annual out-of-pocket
 cost in 2020



Average user
 has **3+** chronic
 conditions

\$6,240

list price for an annual
 supply in 2022

126%

price increase
 since 2012



Costs 80% less
 in Australia



Costs 83% less
 in Canada



Costs 50% less
 in France

\$21.3 Billion*

in global sales

*Boyer reports an additional \$2.1 billion
 in sales from Xarelto.

Since launching Xarelto,
 Johnson & Johnson has spent:

\$29.1 Billion

on marketing

\$25.17 Billion

in total Medicare spending
 since launch

\$71.9 Billion

on stock buybacks

\$75.8 Million

on lobbyists

EXPLOITING PATENTS, PADDING PROFITS

J&J has gamed the patent system to thwart generic competition for Xarelto for
 an additional 4 years, protecting an estimated \$9.7 billion in U.S. revenue.

Primary patent expiry: 2020

43 patent applications

Last patent expiry: 2034

23 patents granted

*Johnson & Johnson and Boehr share a licensing agreement for Xarelto; J&J is responsible for U.S. pricing.